Jun 16, 2014 by Brian Orelli, PhDShould Pfizer Buy Bristol-Myers Squibb Instead of AstraZeneca?Yes, Pfizer should buy Bristol-Myers Squibb instead of AstraZeneca, but it won't.
Jun 16, 2014 by Brian Orelli, PhDDon't Get Too Excited About GW Pharmaceuticals' Fast TrackGW Pharmactuicals' fast track designation says more about the disease its drug treats than the drug itself.
Jun 16, 2014 by Brian Orelli, PhDOur Drug Works! But There's a Catch ...Rather than investing in AFFiRiS and its placebo-turned-drug, investors should look at large companies such as Eli Lilly, Merck, and Biogen Idec for Alzheimer's disease drugs.
Jun 11, 2014 by Brian Orelli, PhDMannKind Corporation's Date With DestinyWill MannKind's Afrezza get approved and compete with injected mealtime insulins from Eli Lilly and Novo Nordisk.
Jun 10, 2014 by Brian Orelli, PhDOrexigen's Date With DestinyOrexigen's Contrave should be approved this week, but will it be able to perform better than obesity drugs from Arena Pharmaceuticals and VIVUS?
Jun 10, 2014 by Brian Orelli, PhDWhat Was Merck Thinking Buying Idenix Pharmaceuticals?Merck buys Idenix Pharmaceuticals and Achillion and Gilead Sciences react.
Jun 9, 2014 by Brian Orelli, PhDIt's a Placebo, It's a Drug, Wait: It's BothAFFiRiS claims its placebo is an active drug.
Jun 6, 2014 by Brian Orelli, PhDIs AstraZeneca Making a Big Mistake With Its Pipeline?AstraZeneca publishes data on its pipeline progress over five years, but investors in Merck, Vertex Pharmaceuticals, and other drug developers should be worried about using the average success rate.
Jun 5, 2014 by Brian Orelli, PhDBiotech Dilemma: When a Loan Isn't Non-DilutiveRetrophin takes out a convertible note. As Dendreon has shown, taking on debt can be dangerous if the company can't pay it back. Investors should look for companies like Seattle Genetics and Regeneron Pharmaceuticals that have assets they can sell to slow the cash burn.
Jun 5, 2014 by Brian Orelli, PhDVertex Pharmaceuticals Inc.'s Date With DestinyVertex Pharmaceuticals combination therapy could treat the underlying condition in cystic fibrosis patients, something drugs from Gilead Sciences and Novartis can't do.
Jun 4, 2014 by Brian Orelli, PhDDon't Hold Your Breath Waiting for a VIVUS Inc. BuyoutAspen Investments discloses that it's considering a buyout of VIVUS. How will that effect fellow obesity drugmakers Arena Pharmaceuticals and Orexigen.
Jun 4, 2014 by Brian Orelli, PhDASCO: Cancer Drug ShowdownAriad, Pharmacyclics, and Johnson & Johnson present impressive data. Clovis battles with AstraZeneca.
Jun 4, 2014 by Brian Orelli, PhDASCO: Bristol-Myers Squibb and Merck Don't DisappointBristol-Myers Squibb's and Merck's immuno-oncology drugs were the highlight of ASCO.
May 31, 2014 by Brian Orelli, PhDIs Over-the-Counter Cialis Coming to a Pharmacy Near You?Eli Lilly and Sanofi try to follow in Merck's and Pfizer's footsteps, converting their prescription drugs to over-the-counter status.
May 27, 2014 by Brian Orelli, PhDObesity Hype Meets Harsh RealityArena Pharmaceuticals' and VIVUS' obesity drugs have struggled out of the gate, which could be good news for Orexigen.
May 27, 2014 by Brian Orelli, PhDBiotech 101: RNA DrugsThe Biotech Banter crew goes over the new class of drugs being developed by Isis Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Research, and others.
May 27, 2014 by Brian Orelli, PhDPicking Up the Pieces: Where AstraZeneca and Pfizer Go From HerePfizer and AstraZeneca decide to go their separate ways. For now.
May 27, 2014 by Brian Orelli, PhD and Dave WilliamsonBiotech Tweet of the Week: The Best of ASCO Is Yet to ComeASCO abstracts were released earlier this month, but we haven't seen data on drugs from AstraZeneca, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, and Merck just yet.
May 22, 2014 by Brian Orelli, PhDTeva Pharmaceutical Industries Ltd. Gets a Taste of its Own MedicineMylan, Momenta Pharmaceuticals, and Novartis appear close to gaining FDA approval of generic versions of Teva Pharmaceutical's Copaxone.
May 21, 2014 by Brian Orelli, PhDPfizer's Other Aggressive PlayTurning from AstraZeneca back to the pipeline.
